News and Announcements
OZ Medicann to expand corporate structure enhancing its ability to provide products for the Australian and International markets
- Published February 28, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OZ Medicann Pty Ltd is enhancing its ability to provide class-leading, patient-centric, development and supply medicinal cannabis products for the Australian and International markets
The restructure which will involve the creation of a new head company, Oz Medicann Group Pty Ltd, under which will reside:
- Oz Medicann P/L focused primarily on the cultivation, research, production and supply of
medicinal cannabis solutions - Educann P/L which will deliver education, certification and accreditation to the medical
practitioners and medicinal cannabis prescribers, and - Hemp OZ P/L commercialise related products and services that are derived from the cannabis
plant.
All entities will generate sustainable revenue that will fund the short and medium and longer terms growth of the Group.
Unlike other medicinal cannabis companies, the OZ Medicann Group will control the entire medicinal cannabis supply chain, from seedling to researcher to patient. The objective of the OZ Medicann Group is to deliver the highest quality medicinal and therapeutic solutions to those who most need them the most – the Patients. With its focus on the sustainable production of high-quality medicinal cannabis solutions, the company will derive revenue from all sources in order to support this outcome.
The OZ Medicann Group is also pleased to announce the appointment of Lucy Haslam to its Board of Directors. Having Lucy on the Board further cements the Group’s commitment to patient-centric research and production and supply of medicinal cannabis solutions. Lucy is the leading advocate and driving force behind the legalisation of medicinal cannabis in Australia and we are thrilled to have Lucy join our team.
The OZ Medicann Group is also pleased to announce, in partnership with United in Compassion, the commencement soon of the largest patient-centric research on medicinal cannabis use in this country. A final announcement will be made shortly on the research partner who will undertake the survey.
The Group’s licence applications are with the Office of Drug Control and are being assessed for production, supply and research. The Group’s growing facility preparations are underway anticipated for quarter 4.
About OZ Medicann
OZ Medicann is a leading Australian Cannabis and Hemp cultivator that produces medicinal solutions, consumer products and education programs for medical practitioners.
Company Updates
Ecosystems Over Exit: Callum Laing on Disrupting Small Business M&A
At Emergence Singapore, Callum Laing of Veblen Director Program presented a bold new vision for small business M&A: “Ecosystems Over Exit.” He shared how his Unity Group takes cash-generating businesses public, focusing on growth over immediate founder exit. Discover his unique approach, how interconnected ecosystems drive massive deal flow, and a three-step framework for any business to amplify reach and capital raising.
Report on the Impact of the Proposed Unrealised Capital Gains Tax on Investment in Key Sectors
A recent survey of investors and company leaders reveals significant concerns about the proposed Unrealised Capital Gains Tax (UCGT) in Australia. Over 84% indicate it would negatively impact investment in vital renewable energy, sustainability, and life science sectors, with 82% believing it would discourage long-term holdings. The report highlights the critical role of SMSF investors in early-stage funding and urges policymakers to reconsider the tax’s potential to stifle innovation and economic growth.
Ray Dalio: “Worse Than a Recession” if Global Imbalances Aren’t Addressed
Ray Dalio, the influential founder of the world’s largest hedge fund, Bridgewater Associates, has issued a grave warning about the global economic and geopolitical landscape, cautioning that without decisive action, the world could face a crisis “worse than a normal recession.” Speaking on “Meet the Press” ahead of the June release of his new book, […]
Backed By Leading Investment Groups and Family Offices
